SNDX
Syndax Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -8.3% ·
share flow -19.2% ·
net new positions -9.1%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 62.71K | $1.14M | n/a | −1 |
| Q2 2026 | 93 | 0 | 57.47M | $1.26B | +9 | −10 |
| Q1 2026 | 97 | +6 | 52.14M | $1.22B | +10 | −4 |
| Q4 2025 | 91 | -3 | 57.71M | $1.21B | n/a | −3 |
| Q3 2025 | 20 | +1 | 39.69M | $610.59M | +1 | n/a |
| Q2 2025 | 16 | +1 | 29.55M | $276.77M | +1 | n/a |
| Q1 2025 | 12 | -1 | 16.71M | $205.25M | n/a | −1 |
| Q4 2024 | 13 | +1 | 16.01M | $211.65M | +1 | n/a |
| Q3 2024 | 11 | -1 | 14.02M | $269.82M | n/a | −1 |
| Q2 2024 | 12 | n/a | 17.35M | $356.12M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 4.99M | -32.1% | $95.98M | 0.0% | ▼ Trim | 2 | SEC ↗ ×7 |
| 2 | Point72 Asset Management ✦ | 2.78M | -0.2% | $53.48M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.98M | +3.5% | $38.07M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 1.12M | +5.1% | $21.56M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Marshall Wace ✦ | 989.90K | -45.9% | $19.06M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 886.49K | -4.8% | $17.07M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 817.60K | -4.9% | $15.74M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 352.36K | +140.3% | $6.78M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 9 | T. Rowe Price ✦ | 48.93K | +1.5% | $942,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 34.02K | -82.1% | $654,885 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 25.42K | -6.8% | $489,316 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Renaissance Technologies | $4.40M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 244 holders, 99.11M shares, $2.29B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.